Pyxis Oncology Inc.

0.88
-0.06 (-5.93%)
At close: Apr 04, 2025, 11:00 AM

Company Description

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers.

Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.

The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome.

The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Pyxis Oncology Inc.
Pyxis Oncology Inc. logo
Country United States
IPO Date Oct 8, 2021
Industry Biotechnology
Sector Healthcare
Employees 44
CEO Dr. Lara S. Sullivan M.D., MBA

Contact Details

Address:
35 Cambridgepark Drive
Cambridge, Massachusetts
United States
Website https://www.pyxisoncology.com

Stock Details

Ticker Symbol PYXS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001782223
CUSIP Number 747324101
ISIN Number US7473241013
Employer ID 83-1160910
SIC Code 2834

Key Executives

Name Position
Dr. Lara S. Sullivan M.D., MBA Chief Executive Officer, President, Chief Medical Officer & Director
Dr. Balu N. Balasubramanian Ph.D. Interim Chief Technology Officer
Pamela Yanchik Connealy M.B.A. Chief Financial Officer & Chief Operating Officer
Dr. Charles T. Gombar Ph.D. Senior Vice President of Portfolio & Program Management
Dr. Jan Pinkas Ph.D. Chief Scientific Officer
Dr. Michael Bui Head of Global Regulatory Affairs
Jitendra Wadhane Chief Accounting Officer, Senior Vice President of Finance & Corporate Controller
Sondra Smyrnios Head of Global Clinical Operations
Stephen T. Worsley MBA Senior Vice President & Chief Business Officer
Thuy Craveiro Pharm.D. Vice President & Head of Clinical Pharmacology

Latest SEC Filings

Date Type Title
Apr 02, 2025 SCHEDULE 13D/A [Amend] Filing
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing